Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma. They give unprecedented anti-tumor responses but acquisition of resistance ultimately limits their clinical benefit. The master regulators driving the expression of resistance-genes remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Corre, Sébastien, Tardif, Nina, Mouchet, Nicolas, Leclair, Héloïse M., Boussemart, Lise, Gautron, Arthur, Bachelot, Laura, Perrot, Anthony, Soshilov, Anatoly, Rogiers, Aljosja, Rambow, Florian, Dumontet, Erwan, Tarte, Karin, Bessede, Alban, Guillemin, Gilles J., Marine, Jean-Christophe, Denison, Michael S., Gilot, David, Galibert, Marie-Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235830/
https://www.ncbi.nlm.nih.gov/pubmed/30429474
http://dx.doi.org/10.1038/s41467-018-06951-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235830/
https://www.ncbi.nlm.nih.gov/pubmed/30429474
http://dx.doi.org/10.1038/s41467-018-06951-2

Ejemplares similares